Drug Approval | October 19, 2021
MSN Labs launches drug for diabetes management
The company claims that its Empagliflozin tablets are the most affordable in India
The company claims that its Empagliflozin tablets are the most affordable in India
The company operates four mid-sized hospitals with a total bed capacity of 556 in eastern India
It has planned an investment of over Rs 80 crore in the next five years
An amount of Rs. 70.9 crore has been earmarked for funding capital expenditure for the proposed expansion
The applicants will only have to get their Good Manufacturing Practices certification validated every five years to retain their licence
The company claims to be a market leader in core orthopaedic and gynaecology segments like bone and joint disorders, pain management and, pregnancy and women’s nutrition
The consideration for the medicines in India is valued at Rs 180.48 crore
The issue will consist of the issuance of fresh equity shares worth up to Rs 331.60 crore and an offer for sale (OFS) of Rs 500 crore by promoters and existing shareholders
A total of 707 district hospitals across all states and union territories participated in the performance assessment. The Health Management Information System (HMIS) data for the year 2017–18 has been used as a baseline for this exercise
These pouches, manufactured at UFlex India plant, will be exported to American markets and will be majorly used for packing edible products
Subscribe To Our Newsletter & Stay Updated
